Syndax Pharmaceuticals names new chief commercial officer
19 March 2024 -

Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company, announced on Monday that it has named Steven Closter as its new chief commercial officer, effective immediately.

In the new role, Closter is to head the firm's commercial strategy and operations, which includes marketing, sales, and market access. He will succeed Steve Sabus, who is departing for personal reasons.

Closter has more than 30 years of commercial experience. He has served in various roles at Sunovion Pharmaceuticals, and has served for around 20 years in senior marketing and commercial roles at Forest Laboratories and Allergan. He most recently served as vice president, Marketing.